GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up. I think Lilly is a no-brainer opportunity for investors with a long ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

This has lagged the Medical sector's gain of 1. ... be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled ...

The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis ...

Here's what Wall Street analysts say about the inclusion: Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company ... Lilly said on Monday it has sued two ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...